Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NovoCure (NVCR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.04 per share a year ago.

NovoCure (NVCR) Reports Q1 Loss, Lags Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports First Quarter 2023 Financial Results.

Novocure Reports First Quarter 2023 Financial Results

Senseonics Holdings

Veeva Systems

In discussing healthcare tech stocks, it pays to understand what healthcare technology is broadly. Healthcare technology, also known as HealthTech, refers to any technology developed to improve the healthcare system.

The 3 Most Promising Healthcare Tech Stocks for April 2023

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6. The LUNAR study is a phase 3, open-label, randomized study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with standard therapies.

Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced 27 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida.

Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the first quarter 2023 on May 4, 2023, before the U.S. financial markets open.

Novocure to Report First Quarter 2023 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure's Board of Directors. “We look forward to welcoming Ms. Stafford to our board of directors,” said William Doyle, Novocure's Executive Chairman. “Her broad expertise in finance in the life sciences sector and experience with a leading funder of innovation across the biopharmaceutical industry will be valuable as our global organization prepares for future growth.” Ms.

Kristin Stafford Joins Novocure Board of Directors

NovoCure has seen strong growth over the past decade but is unable to post profits with large sums invested into the pipeline. After softer sales momentum, pipeline conversion to other cancer types is necessary to drive appeal.

NovoCure: Pipeline Conversion Is Key

NovoCure focuses on promoting Optune and Optune Lua, FDA-approved devices utilizing Tumor Treating Fields (TTFields) technology to target and destroy cancer cells. The LUNAR study in non-small cell lung cancer (NSCLC) met its primary endpoint, showing significant improvement in overall survival when using TTFields with standard therapies. Details are expected in June.

Exploring The Potential Of NovoCure's TTFields In Non-Small Cell Lung Cancer

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.

Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Zai Lab Ltd.

The bear market has been brutal to small and unprofitable biopharma stocks. Zai Lab plans to commercialize a baffling number of its programs, and soon.

2 Stocks That Could Rebound and Rise 30% or More in 2023

Axon Enterprise

The central bank's plan to aggressively hike interest rates might trigger a sharp correction in U.S. stock markets. Axon Enterprise and NovoCure are two companies with economically insensitive business models, making them ideal safe-haven plays.

2 Best Defensive Stocks to Buy in March

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering Optune on the List of Reimbursable Products and Services (LPPR) provided for in Article L165-1 of the Social Security Code was published in the Official Journal on February 28, 2023 and will become effective March 15, 2023.

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced that the final patient has enrolled in the pivotal METIS study.

Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Investors were looking for a stronger Q4 from the cancer company.

Why NovoCure Stock Is Falling Today

Novocure Limited (NASDAQ:NVCR ) Q4 2022 Results Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Pritesh Shah - Chief Growth Officer Conference Call Participants Na Sun - JPMorgan Chase & Co. Jason Wittes - Loop Capital Lei Huang - Wells Fargo Jason Bednar - Piper Sandler Greg Fraser - Truist Securities Vijay Kumar - Evercore ISI Emily Bodnar - H.C. Wainwright Ingrid Goldberg Good morning, everyone, and thank you for joining us to review Novocure's Fourth Quarter and Full Year 2022 Performance.

Novocure Limited (NVCR) Q4 2022 Earnings Call Transcript

NovoCure (NVCR) delivered earnings and revenue surprises of -12.50% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Allyson J. Ocean, M.D., has been elected to Novocure's Board of Directors. Dr. Ocean brings decades of experience in oncology to Novocure.

Allyson J. Ocean, M.D., Joins Novocure Board of Directors

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for

There was good news from the laboratory on Hump Day.

Why Novocure Stock Was so Healthy Today

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced that the final patient has been enrolled in the pivotal PANOVA-3 study.

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

As NovoCure Limited delivers hope in seemingly hopeless situations, Tumor Treating Field is already launched for mesothelioma and glioblastoma multiforme. NovoCure Limited recently generated stellar data for the Phase 3 (LUNAR) trial for non-small cell lung cancer.

NovoCure: Ramifications Of Recent Management Change

Catalyst Pharmaceuticals

iShares Nasdaq Biotechnology ETF

Inspire Medical Systems Inc

Revance Therapeutics

Teva Pharmaceutical

Vertex Pharmaceuticals

Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.

Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride

Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs.

News for Novocure Stock (NVCR)